#Melanoma is an active hashtag on Bluesky. In the last 30 days, 48 people shared 84 posts with it — around 3 a day. Activity is down 24% versus the previous week, peaking on Jul 18 with 6 posts.
Ashley Holden 🩷 M.Ed. @mrsholden2019.bsky.social
Fighting #cancer is the hardest thing I've ever done. It's been an 18 year battle - now stage 4. I need to raise $ for my full body PET scan & the $4,900 Signatera tests (4x a year) insurance doesn't cover. 🔗 www.gofundme.com/f/help-a-mom... Please SHARE and help if you're able. I'm grateful. ❤️
www.gofundme.com
Kathleen Bachynski @bachynski.bsky.social
“Many dermatologists were dismayed when Kennedy abruptly withdrew a proposed FDA rule that would have banned minors from using devices that mimic sunlight — indoor tanning lamps... [the rule] would have also required indoor tanning facility users to sign a form acknowledging the risk of cancer”
www.latimes.com
rdcu.be
Peripheral positioning of lysosomes supports melanoma aggressiveness
Nature Communications - The function and position of organelles are pivotal for tumor cell dissemination. Here the authors use melanoma patient samples and animal models to show that peripheral...
Ashley Holden 🩷 M.Ed. @mrsholden2019.bsky.social
Fighting #cancer is the hardest thing I've ever done. It's been an 18 year battle - now stage 4. I need to raise $ for my full body PET scan & the $4,900 Signatera tests (4x a year) insurance doesn't cover. 🔗 www.gofundme.com/f/help-a-mom... Please SHARE and help if you're able. I'm grateful. ❤️
www.gofundme.com
dlvr.it
It took three tries, but this tumor-injecting melanoma drug finally got FDA approval
After two rejections and a regulatory standoff tied to the Makary era at FDA, Replimune's Tudriqev won accelerated approval for advanced melanoma patients who've run out of immunotherapy options. The virus-based drug — injected directly into tumors — is only the second approved treatment for this hard-to-treat group, though its $450,000 list price and single-arm trial design still draw scrutiny.
statnews.com
Pharmalittle: We're reading about Replimune's melanoma drug, a Medicare policy change, and more
Eli Lilly and Novo Nordisk convinced a federal judge to toss an antitrust lawsuit by a compound pharmacy
www.onclive.com
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma | OncLive
Michael Wong, MD, PhD, FRPC, discusses the FDA accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in melanoma.
agentictribune.com
FDA Grants Accelerated Approval to Replimune’s Tudriqev for PD-1–Resistant Advanced Melanoma
FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.
frontiersin.org
frontiersin.org
Ashley Holden 🩷 M.Ed. @mrsholden2019.bsky.social
Fighting #cancer is the hardest thing I've ever done. It's been an 18 year battle - now stage 4. I need to raise $ for my full body PET scan & the $4,900 Signatera tests (4x a year) insurance doesn't cover. 🔗 www.gofundme.com/f/help-a-mom... Please SHARE and help if you're able. I'm grateful. ❤️
www.gofundme.com
www.targetedonc.com
First Patients Dosed With DOC1021 in Phase 1/2 Melanoma Trial | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.
www.curetoday.com
FDA Advisory Committee Backs RP1 for Advanced Melanoma | CURE
The 10-3 vote came during a discussion in which the limitations of TIL therapy, the only approved option for this group of patients, were raised repeatedly.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
